CVE-2022-21566
published 2022-07-19CVE-2022-21566: Vulnerability in the Oracle Applications Framework product of Oracle E-Business Suite (component: Diagnostics). Supported versions that are affected are…
PriorityP349high7.5CVSS 3.1
AVNACLPRNUINSUCHINAN
EPSS
0.91%
55.7th percentile
Vulnerability in the Oracle Applications Framework product of Oracle E-Business Suite (component: Diagnostics). Supported versions that are affected are 12.2.9-12.2.11. Easily exploitable vulnerability allows unauthenticated attacker with network access via HTTP to compromise Oracle Applications Framework. Successful attacks of this vulnerability can result in unauthorized access to critical data or complete access to all Oracle Applications Framework accessible data. CVSS 3.1 Base Score 7.5 (Confidentiality impacts). CVSS Vector: (CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:N/A:N).
Affected
7 ranges
| Vendor | Product | Version range | Fixed in |
|---|---|---|---|
| msrc | microsoft_visual_studio_2017_version_15.9 | — | — |
| msrc | microsoft_visual_studio_2019_version_16.11 | — | — |
| msrc | microsoft_visual_studio_2022_version_17.0 | — | — |
| msrc | microsoft_visual_studio_2022_version_17.2 | — | — |
| msrc | microsoft_visual_studio_2022_version_17.4 | — | — |
| oracle | applications_framework | 12.2.9 – 12.2.11 | — |
| oracle_corporation | applications_framework | — | — |
CVSS provenance
nvdv3.17.5HIGHCVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:N/A:N
vendor_msrc7.8HIGH
vendor_oracle7.5HIGH
Stop checking back — get the weekly exploitation signal.
Every Monday: what got weaponized or added to CISA KEV in the last seven days — each CVE cross-linked to its PoC, Nuclei template, and detection rule. Free, one email a week, unsubscribe in one click.
Microsoft
Visual Studio Elevation of Privilege Vulnerability
vendor_msrc·2023-02-14·CVSS 7.8
CVE-2023-21566 [HIGH] CWE-73 Visual Studio Elevation of Privilege Vulnerability
Visual Studio Elevation of Privilege Vulnerability
FAQ: What privileges could be gained by an attacker who successfully exploited this vulnerability?
An attacker who successfully exploited this vulnerability could gain SYSTEM privileges.
Visual Studio: Visual Studio
Microsoft: Microsoft
Customer Action Required: Yes
Impact: Elevation of Privilege
Exploit Status: Publicly Disclosed:No;Exploited:No;Latest Software Release:Exploitation Less Likely;Older Software Release:Exploitation Less Likely;DOS:N/A
Remediation: Release Notes
Reference: https://my.visualstudio.com/Downloads?q=Visual Studio 2022 version 17.2
Reference: http://aka.ms/vs/15/release/latest
Reference: https://my.visualstudio.com/Downloads?q=Visual Studio 2022 version 17.4
Reference: https://my.visualstudio.com/Downlo
Oracle
Oracle Oracle E-Business Suite Risk Matrix: Diagnostics — CVE-2022-21566
vendor_oracle·2022-07-15·CVSS 7.5
CVE-2022-21566 [HIGH] Oracle Oracle E-Business Suite Risk Matrix: Diagnostics — CVE-2022-21566
Oracle Oracle E-Business Suite Risk Matrix: Diagnostics vulnerability
CVE: CVE-2022-21566
CVSS: 7.5
Protocol: HTTP
Remote exploit: Yes
Affected versions: Network
Advisory: cpujul2022 (JUL 2022)
GHSA
GHSA-frj6-3m84-3f83: Vulnerability in the Oracle Applications Framework product of Oracle E-Business Suite (component: Diagnostics)
ghsa_unreviewed·2022-07-20
CVE-2022-21566 [HIGH] GHSA-frj6-3m84-3f83: Vulnerability in the Oracle Applications Framework product of Oracle E-Business Suite (component: Diagnostics)
Vulnerability in the Oracle Applications Framework product of Oracle E-Business Suite (component: Diagnostics). Supported versions that are affected are 12.2.9-12.2.11. Easily exploitable vulnerability allows unauthenticated attacker with network access via HTTP to compromise Oracle Applications Framework. Successful attacks of this vulnerability can result in unauthorized access to critical data or complete access to all Oracle Applications Framework accessible data. CVSS 3.1 Base Score 7.5 (Confidentiality impacts). CVSS Vector: (CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:N/A:N).
No detection rules found.
No public exploits indexed.
No writeups or analysis indexed.
2022-07-19
Published